Literature DB >> 20945984

Biomarkers in Parkinson's disease: a funder's perspective.

Mark Frasier1, Sohini Chowdhury, Jamie Eberling, Todd Sherer.   

Abstract

Therapeutic development in Parkinson's disease is hampered by the paucity of well-validated biomarkers that can assist with diagnosis and/or tracking the progression of the disease. Since its inception, the Michael J Fox Foundation for Parkinson's Research has invested heavily in biomarker research and continues to prioritize discovery and development efforts. This article summarizes the history and evolution of the Michael J Fox Foundation's role in supporting biomarker research and lays out the current challenges in successfully developing markers that can be used to test therapies, while also providing a vision of future funding efforts in Parkinson's disease biomarkers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20945984     DOI: 10.2217/bmm.10.89

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  3 in total

1.  Changes in the Serum Urate Level Can Predict the Development of Parkinsonism in the 6-Hydroxydopamine Animal Model.

Authors:  Mohammad Reza Sarukhani; Hashem Haghdoost-Yazdi; Gilda Khandan-Chelarci
Journal:  Neurochem Res       Date:  2018-04-03       Impact factor: 3.996

2.  Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease.

Authors:  Tiziana Alberio; Agnese C Pippione; Maurizio Zibetti; Simone Olgiati; Daniela Cecconi; Cristoforo Comi; Leonardo Lopiano; Mauro Fasano
Journal:  Sci Rep       Date:  2012-12-11       Impact factor: 4.379

Review 3.  Methodological challenges and analytic opportunities for modeling and interpreting Big Healthcare Data.

Authors:  Ivo D Dinov
Journal:  Gigascience       Date:  2016-02-25       Impact factor: 6.524

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.